Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
Subjects were previously vaccinated at 11 to 17 years of age. This extension phase starts 24
 months after vaccination and the subjects who were vaccinated in the primary study will be
 enrolled in this extension phase. No new subjects will be enrolled.
Subjects were previously vaccinated at 11 to 17 months of age with GSK Biologicals'
 meningococcal vaccine 134612 or with Mencevax™. This extension phase starts 24 months after
 vaccination and the subjects who were vaccinated in the primary study will be enrolled in
 this extension phase. No new studies will be enrolled. The subjects will have 4 blood samples
 taken: at 24, 36, 48 and 60 months after vaccination.
Inclusion Criteria:

 -  Subjects who the investigator believes that they and/or their parent(s)/guardian(s)
 can and will comply with the requirements of the protocol should be enrolled in the
 study.

 -  A male or female having been vaccinated with a meningococcal vaccine in the primary
 study 109069.

 -  Written informed consent obtained from parent(s)/guardian(s) of the subject and
 written informed assent obtained from the subject if the subject is less than 18 years
 of age, or written informed consent obtained from the subject if the subject has
 achieved the 18th birthday.

 -  Healthy subjects as established by medical history and clinical examination before
 entering into the study.

 Exclusion Criteria:

 -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
 preceding the subject's first visit.

 -  History of meningococcal disease; such cases will be documented.

 -  Administration of a meningococcal polysaccharide or a meningococcal polysaccharide
 conjugate vaccine since previous vaccination in study 109069.

 -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
 medical history.

 -  Administration of immunoglobulins and/or any blood products within the three months
 preceding the subject's first visit.

 -  Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy

 -  Subjects who withdrew consent to be contacted for follow-up studies.